Kurt R. Brunden, PhD
Research Professor of Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
Contact InformationCenter for Neurodegenerative Disease Research
University of Pennsylvania
3600 Spruce St.
3rd Floor Maloney Bldg.
Philadelphia, PA 19104
Office: 215-615-5262
Email: kbrunden@upenn.edu
Specialty Division
Immunobiology and Experimental Pathology
Research Expertise
Dr. Brunden oversees research programs directed towards the identification of therapeutic targets and treatments for Alzheimer's, Parkinson's and other neurodegenerative diseases.
Itmat Expertise
Dr. Brunden oversees research programs directed towards the identification of therapeutic targets and treatments for Alzheimer's, Parkinson's and other neurodegenerative diseases.
Education
B.S. (Biology/Health Chemistry), Western Michigan University, 1980
Ph.D. (Biochemistry), Purdue University, 1985
Specialty Certification
Postgraduate Training
Post-docotoral fellow, Mayo Clinic and Foundation, 1985-1987
Instructor and Research Assoc., Mayo Clinic and Foundation, 1988-1988
Awards and Honors
Merck Award; Department of Chemistry; Western Michigan University, Kalamazoo, MI, 1980
Graduated Magna Cum Laude; 1980; Western Michigan University; Kalamazoo, MI, 1980
N.I.H. Competitive Predoctoral Training Award; Purdue University, West Lafayette, IN, 1981-1984
Outstanding Research Award; Department of Neurology; Mayo Clinic,
Rochester, MN, 1987
Travel Award; American Society for Neurochemistry, 1988
Memberships and Professional Organizations
Society for Neuroscience, 1991 - Present
American Association for the Advancement of Science, 1992 - 2008
American Chemical Society, 2005 - 2008
Chartered Member, NIH NINDS NSD-C Study Section, 2009 - 2012
Chair, NIH NINDS NSD-C Study Section, 2010 - 2012
Scientific Review Board, Alzheimer's Disease Drug Discovery Foundation, 2010 - Present
NIH-NCATS Therapeutics Discovery Special Emphasis Panel, 2012 - Present
NIH NINDS NSD-A Study Section, 2014 - 0214
NIH NIA U01 Drug Development Study Section, 2015 - Present
NIH NINDS Epilepsy CWOW Study Section, 2015 - 2015
Selected Publications
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.
Makani V, Zhang B, Han H, Yao Y, Lassalas P, Lou K, Paterson I, Lee VM-Y, Trojanowski JQ, Ballatore C, Smith AB III and Brunden KR, Acta Neuropathol. Comm. In press(): , 2016
Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer’s disease and related tauopathies
Kovalevich J, Cornec A-S, Yao Y, James M, Crowe A, Lee VM-Y, Trojanowski JQ, Smith AB III, Ballatore C and Brunden KR, J. Pharm. Exp. Therap. 357(): 432-450, 2016
The dynamics and turnover of tau aggregates in cultured cells: insights into therapies for tauopathies.
Guo JL, Buist A, Soares A, Callaerts K, Calafate S, Stevenaert F, Daniels JP, Zoll BE, Crowe A, Brunden KR, Moechers D and Lee V-MY, J. Biol. Chem. 291(): 13175-13193, 2016
Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors.
Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX and Brunden KR, Scientific Reports 5(): 18286, 2015
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranaraynan S, Barten D, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Kennan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan V, Cacace A, Albright CF, Meredith J, Trojanowski JQ, Lee V-MY, Brunden KR* and Ahlijanian M* (*Co-corresponding authors), PlosONE 10(): e0125614, 2015
Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.
Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken, M, Brunden KR, Trojanowski JQ, Dewachter I; Lee VM and Moechers D, Neurobiol. Dis. 73(): 83-95, 2015
Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.
Cornec A-S, James M, Kovalevich J, Trojanowski JQ, Lee VM-Y, Smith AB III, Ballatore C and Brunden KR, Bioorg. Med. Chem. Lett. in press(): , 2015
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer’s disease and related tauopathies.
65. Lou K, Yao Y, Hoye A, James M, Cornec A, Hyde E, Gay B, Lee VM-Y, Trojanowski JQ, Smith AB III, Brunden KR* and Ballatore C* (*Co-corresponding authors), J. Med. Chem. 57(): 6116-27, 2014
Potent, long-acting cyclopentane-1,3-dione thromboxane (A2) receptor antagonists.
66. Wang X, Liu L, Huang L, Herbst-Robinson K, Cornec A, James M, Sugiyama S, Bassetto M, Brancale A, Trojanowski JQ, Lee VM-Y, Smith AB III, Brunden KR* and Ballatore C* (*Co-corresponding authors), ACS Med. Chem. Lett. 5(): 1015-20, 2014
Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.
Ballatore C, Gay B, Huang L, Herbst-Robinson K, James M, Trojanowski JQ, Lee VM-Y, Brunden KR and Smith AB III, Bioorg. Med. Chem. Lett. 24(): 4171-75, 2014
